Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Journal article published in 2015 by C. van de Velde, Ariel Zwenger, Y. Wang, Z. Wang, T. Watanabe, T. Whelan, N. Wilcken, E. Winer, N. Wolmark, W. Wood, J. Burrett, M. Clarke, Ebctcg Early Breast Cancer Trialists' Collaborative Group, R. Bradley, F. Duane and other authors.

This paper is available in a repository.

Full text: Download

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload

The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.